JOHOR BAHRU, Malaysia, April 2, 2018 /PRNewswire/ -- His Majesty Sultan Ibrahim Ibni Almarhum Sultan Iskandar, the Sultan of Johor, announced yesterday the establishment of a regional centre for cancer treatment, research and education, led by Singapore-headquartered Asian American Medical Group ("AAMG").
The Tunku Laksamana Johor Cancer Centre ("TLJCC") is slated for an end-2020 opening in Iskandar Puteri. Its first phase will offer:
i. Diagnostics and imaging: PET/CT, CT/MRI with liquid biopsy;
ii. Personalised oncology using gene profiling and targeted chemo/immunotherapy; and
iii. Radiation therapy: IMRT, SBRT and VMAT.
AAMG will design and build the private facility, which includes an Integrative Medical Unit combining Western methods with proven traditional therapies for holistic treatment, and a two-acre healing garden donated by His Majesty.
"Johor will be the first in Malaysia, and indeed in this region, to have such a comprehensive specialist cancer centre. This is the latest in a series of initiatives by the Johor Royal Family to bring advanced cancer treatment to Johor," said Sultan Ibrahim.
Phase 1 has a gross development value of RM300 million (US$77 million) and built-up area of approximately 14,000sqm - including an ambulatory facility with 30 day beds - and can treat up to 7,000 patients annually. It is within driving distance of Senai International Airport, Tuas Second Link and Woodlands Causeway.
Plans for Phase 2 include a Syariah-compliant women's wing, operating rooms, a laboratory for nuclear medicine and advanced molecular diagnostics, and a specialist medical mall.
TLJCC will collaborate with global institutions including Concord Medical Services Holdings Ltd. and its appointed partner in Asia, the MD Anderson Cancer Center (USA).
TLJCC is dedicated to His Majesty's third son, Almarhum Tunku Abdul Jalil Iskandar Ibni Sultan Ibrahim, Tunku Laksamana Johor, who died from liver cancer in 2015. To fulfil his dream by alleviating the sufferings of fellow cancer patient, part of the centre's annual profits will be donated to the Tunku Laksamana Johor Cancer Foundation.
"AAMG is proud to collaborate with global partners to ensure TLJCC offers best-in-class clinical outcomes. Apart from serving Malaysians, TLJCC's proximity to Singapore can position Johor as a leading medical destination with the region's best oncological care," said AAMG's Executive Chairman Dato' Dr. Tan Kai Chah.
For more information, visit www.aamg.co or contact ashadevi@wer1.net /roshansingh@wer1.net.
